IP Library Granted Patent US 6,932,777
Granted Patent B2
US 6,932,777 · App. 09/971,901 · Granted Aug 23, 2005

Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer

Assignee: Johns Hopkins University School of Medicine
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,932,777
App. No.
09/971,901
Granted
Aug 23, 2005
Kind
B2
Abstract

The present invention provides prophylactic and therapeutic methods of treating the ductal epithelium of an exocrine gland, in particular a mammary gland, for disease, in particular cancer. The methods comprise contacting the ductal epithelium of the exocrine gland with an epithelium-destroying gent, preferably by ductal cannulation, so as to realize a prophylactic or therapeutic effect.

Claims (17)

1. A method of treating the ductal epithelium of a mammary gland therapeutically for cancer, which method consists of contacting, by ductal cannulation, the ductal epithelium of the mammary gland with a composition consisting of one or more cytotoxic compounds selected from the group consisting of genistein, okadaic acid, 1-β-D-arabinofuranosyl-cytosine, arabinofuranosyl-5-aza-cytosine, cisplatin, carboplatin, actinomycin D, asparaginase, bis-chloro-ethyl-nitroso-urea, bleomycin, chlorambucil, cyclohexyl-chloro-ethyl-nitroso-urea, cytosine arabinoside, duanomycin, etoposide, hydroxyurea, melphalan, mercaptopurine, mitomycin C, nitrogen mustard, procarbazine, teniposide, thioguanine, thiotepa, vincristine, 5-flurouracil, 5-fluorocytosine, cyclophosphamide, methotrexate, vinblastine, doxorubicin, leucovorin, taxol, an anti-estrogen agent, an intracellular antibody against an oncogene, a flavonol, Guan-mu-tong extract, a retinoid, an analogue of a retinoid, and a monoterpene to destroy the ductal epithelium so as to inhibit the spread of cancer.

2. The method of claim 1 , wherein the one or more cytotoxic compounds is doxorubicin.

3. The method of claim 2 , wherein the one or more cytotoxic compounds is 5-fluorouracil.

4. The method of claim 3 , wherein the one or more cytotoxic compounds is cyclophosphamide.

5. The method of claim 1 , wherein the one or more cytotoxic compounds is 5-fluorouracil.

6. The method of claim 5 , wherein the one or more cytotoxic compounds is cyclophosphamide.

7. The method fo claim 1 , wherein the one or more cytotoxic compounds is cyclophosphamide.

8. The method of claim 7 , wherein the one or more cytotoxic compounds is doxorubicin.

9. A method of treating the ductal epithelium of a mammary gland therapeutically for cancer, which method consists of contacting, by ductal cannulation, the ductal epithelium of the mammary gland with a composition consisting of (i) one or more cytotoxic compounds selected from the group consisting of genistein, okadaic acid, 1-β-D-arabinofuranosyl-cytosine, arabinofuranosyl-5-aza-cytosine, cisplatin, carboplatin, actinomycin D, asparaginase, bis-chloro-ethyl-nitroso-urea, bleomycin, chlorambucil, cyclohexyl-chloro-ethyl-nitroso-urea, cytosine arabinoside, duanomycin, etoposide, hydroxyurea, meiphalan, mercaptopurine, mitomycin C, nitrogen mustard, procarbazine, teniposide, thioguanine, thiotepa, vincristine, 5-flurouracil, 5-fluorocytosine, cyclophosphamide, methotrexate, vinblastine, doxorubicin, leucovorin, taxol, an anti-estrogen agent, an intracellular antibody against an oncogene, a flavonol, Guan-mu-tong extract, a retinoid, an analogue of a retinoid, and a monoterpene and (ii) a cytokine or hematopoietic growth factor to destroy the ductal epithelium so as to inhibit the spread of cancer.

10. The method of claim 9 , wherein the one or more cytotoxic compounds is doxorubicin.

11. The method of claim 10 , wherein the one or more cytotoxic compounds is 5-fluorouracil.

12. The method of claim 11 , wherein the one or more cytotoxic compounds is cyclophosphamide.

13. The method of claim 9 , wherein the one or more cytotoxic compounds is 5-fluorouracil.

14. The method of claim 13 , wherein the one or more cytotoxic compounds is cyclophosphamide.

15. The method of claim 9 , wherein the one or more cytotoxic compounds is cyclophosphamide.

16. The method of claim 15 , wherein the one or more cytotoxic compounds is doxorubicin.

17. The method of claim 5 , wherein the hematopoietic growth factor is GM-CSF.

Assignments (1)
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Sep 26, 2008
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021596/0133 →
Continuity (5)
Division 0924020600 · Jan 29, 1999
Continuation 0909314500 · Jun 8, 1998
Division 0869200100 · Aug 2, 1996
Provisional Application 6002892900 · Aug 3, 1995
Related Publication 20020035356A1 · Mar 21, 2002